$FEMY 4 SEC Filings

Filed On	Filing
11 Aug 2026	Form 4: Eichenbaum Kenneth D., Director Granted 880 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Milnes Alistair, Director Granted 880 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Uzialko Edward R, Director Granted 880 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Mifek Jeffrey Gerald, Chief Clinical-Medical Affairs Bought 3,125 shares ($10K) · Granted 3,125 Common Stock Purchase Warrant · Granted 3,125 Common Stock Purchase Warrant (Milestone)
11 Aug 2026	Form 4: Larsen Charles, Director Granted 880 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Mifek Jeffrey Gerald, Chief Clinical-Medical Affairs Granted 6,250 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Canning John Charles, Chief Operating Officer Bought 4,375 shares ($14K) · Granted 4,375 Common Stock Purchase Warrant · Granted 4,375 Common Stock Purchase Warrant (Milestone)
11 Aug 2026	Form 4: Sipos Jeremy Alexander, Chief Technology Officer Bought 3,125 shares ($10K) · Granted 3,125 Common Stock Purchase Warrant · Granted 3,125 Common Stock Purchase Warrant (Milestone)
11 Aug 2026	Form 4: Lee-Sepsick Kathy, Director Bought 15,625 shares ($50K) · Granted 15,625 Common Stock Purchase Warrant · Granted 15,625 Common Stock Purchase Warrant (Milestone)
11 Aug 2026	Form 4: Elefant Dov, Chief Financial Officer Bought 15,625 shares ($50K) · Granted 15,625 Common Stock Purchase Warrant · Granted 15,625 Common Stock Purchase Warrant (Milestone)
01 Apr 2026	Form 4: Canning John Charles, Chief Operating Officer Granted 150,000 Stock Option (Right to Buy)
27 Mar 2026	Form 4: Elefant Dov, Chief Financial Officer Granted 34,122 Series D-1 Warrants
27 Mar 2026	Form 4: Lee-Sepsick Kathy, Director Granted 68,244 Series D-1 Warrants
27 Mar 2026	Form 4: Eichenbaum Kenneth D., Director Granted 102,366 Series D-1 Warrants
27 Mar 2026	Form 4: Larsen Charles, Director Granted 34,122 Series D-1 Warrants
20 Mar 2026	Form 4: Eichenbaum Kenneth D., Director Granted 35,200 Stock Option (Right to Buy)
18 Mar 2026	Form 4: PharmaCyte Biotech, Inc., 10% owner
18 Mar 2026	Form 4: Silverman Joshua, Director
20 Feb 2026	Form 4: Lee-Sepsick Kathy, Director Granted 729,000 Restricted Stock Units
20 Feb 2026	Form 4: Elefant Dov, Chief Financial Officer Granted 342,000 Restricted Stock Units

Comments